18 and older, female only, with Cervical Adenocarcinoma or Cervical Adenosquamous Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With Objective Response Rate (ORR, Either Partial or Complete Response) Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 CriteriaPrimary· Up to 2 years
Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Complete Response (CR) is the disappearance of all lesions and Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) is CR+PR.
Group
Value
95% CI
Treatment (Atezolizumab, Bevacizumab)
0
Progression Free SurvivalSecondary· From start of treatment to investigator determined date of progression, or death due to any cause, whichever occurs first, assessed up to 2 years
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm (0.5 cm) or the appearance of one or more new lesions.
Group
Value
95% CI
Treatment (Atezolizumab, Bevacizumab)
2.9
1.8 – 6
Overall Survival (OS)Secondary· From start of treatment to death, assessed up to 2 years
The duration of OS will be estimated.
Group
Value
95% CI
Treatment (Atezolizumab, Bevacizumab)
8.9
3.4 – 21.9
Percent of Participants With Adverse EventsSecondary· Up to 30 days after the last dose of study treatment, on average of 4 months
The frequency and severity of adverse events will be assessed in those patients who initiate their study treatment.
Group
Value
95% CI
Treatment (Atezolizumab, Bevacizumab)
36.4
PD-L1 Expression on Tumor and Immune Cells Measured by Semi-quantitative ImmunohistochemistrySecondary· Up to 2 years
The efficacy of the combination of atezolizumab and bevacizumab as measured by objective response, will be described in patients according to PD-L1 positive and PD-L1 negative.
Group
Value
95% CI
Treatment (Atezolizumab, Bevacizumab)
3
Intratumoral and Peripheral T-cell Receptor (TCR) Clonality Assessed by TCR SequencingSecondary· Up to 2 years
Will be used to describe the efficacy of the combination of atezolizumab and bevacizumab.
Group
Value
95% CI
Treatment (Atezolizumab, Bevacizumab)
0
Tumor Infiltrating Lymphocyte ProportionSecondary· Up to 2 years
Will be used to describe the efficacy of the combination of atezolizumab and bevacizumab.
Group
Value
95% CI
Treatment (Atezolizumab, Bevacizumab)
1.17
0.06 – 2.77
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to 30 days after the last dose of study treatment, on average of 4 months..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with cervical cancer that has come back, remains despite treatment, or has spread to other places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may shrink tumor cell and interfere with the ability of tumor cells to grow and spread.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer
· Phase 3
· not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
· Phase 2
· not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce
· Phase 2
· recruiting
NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec
· Phase 3
· not yet recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit
· Phase 1, PHASE2
· recruiting
Other recruiting trials for Cervical Adenocarcinoma
Currently open trials in the same condition.
NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda
· Phase 2
· recruiting
NCT06543576 — External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cer
· Phase 1, PHASE2
· recruiting
NCT06654011 — IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Tr
· Phase 2
· recruiting
NCT07153952 — RT for Adenocarcinoma/Adenosquamous Carcinoma
· Phase 1, PHASE2
· active not recruiting
NCT04622670 — Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Pat
· NA
· active not recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem
· Phase 1, PHASE2
· recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem
· Phase 2, PHASE3
· not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa
· Phase 2
· recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After
· Phase 1
· not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 21 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02921269.